Key Highlights
- Shares were down 41.91% to USD 15.00 in intraday trading on November 4, 2026, from an implied prior close of about USD 25.82 (calculated).
- Sanofi decided to discontinue the Phase 1 trial of SAR448272, an oral STAT6 degrader, and terminate the program, per a November 3, 2026 release.
- Nurix does not expect milestones or royalties on that program, but cash of USD 1.1 billion at August 31, 2026 funds operations into the second half of 2029.
- Jefferies reportedly cut its price target from USD 45 to USD 36 and kept a Buy rating, calling the decision a surprise.
What Moved Nurix Therapeutics During Trading (down USD 10.82, 41.91%)
Nurix Therapeutics (NASDAQ:NRIX) was down 41.91% at USD 15.00 in intraday trading on November 4, 2026, a fall of USD 10.82 from an implied prior close of about USD 25.82 (calculated). The slide deepened from roughly 28% in pre-market trading earlier in the day. Volume was about 3.84 million shares, around 1.54 times normal according to the quote. The trigger is a company release dated November 3, 2026, issued after the close, saying partner Sanofi had decided to stop the Phase 1 first-in-human trial of SAR448272 and end the program. The release did not give Sanofi's reasons.
What Does the Sanofi Decision Change?
SAR448272 is an oral degrader aimed at STAT6, a transcription Factor involved in allergic and inflammatory signaling. Nurix said it no longer expects development, regulatory or commercial milestones or royalties from it, though it stays eligible for payments on other licensed programs that Sanofi may advance. Sanofi exercised a license extension option in 2025 covering two transcription factor programs, and Nurix keeps an option to co-develop and co-promote in the United States after clinical proof of concept. According to published coverage, Jefferies said the decision came as a surprise, that management had not seen supporting data and that Sanofi indicated no immediate patient safety concern. That coverage also gave the Jefferies target cut from USD 45 to USD 36 with a Buy rating retained.
Cash, Pipeline and Risks Still in Play
The company said cash, equivalents and marketable securities were USD 1.1 billion at August 31, 2026 and that its runway into the second half of 2029 is unchanged. The intraday quote shows a Market Value of about USD 1.64 billion, so cash is a large share of the valuation, although burn continues. The lead asset, the BTK degrader bexobrutideg, is in a Phase 3 trial in chronic lymphocytic leukemia with Roche, which makes the company dependent on one partner. NX-1607, a CBL-B inhibitor, is in Phase 1b cohorts, and GS-6791 is in Phase 1 with Gilead. Early stage programs can be ended by partners with little warning, and partnered Revenue can disappear when they do. The release listed no upcoming catalysts, so near-term direction may depend on how investors reassess the Partnership model after a sharp, news driven repricing.
Where Things Stand
Nurix Therapeutics (NASDAQ:NRIX) is down 41.91% because Sanofi ended the SAR448272 trial and program, removing a partnered asset and its potential milestones and royalties, and the company gave no reason from Sanofi. The Balance Sheet and runway guidance are unchanged, and the Roche-partnered Phase 3 program is the main value driver. Watch for any further explanation from Sanofi, the status of the second transcription factor program, bexobrutideg updates and the company's next quarterly report.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...